News
MRSN
4.490
+4.42%
0.190
Weekly Report: what happened at MRSN last week (0318-0322)?
Weekly Report · 3d ago
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
5 analysts have shared their evaluations of Mersana Therapeutics during the recent three months. The company is a clinical-stage biopharmaceutical company developing drugs to treat cancer. The average 12-month price target of $6.6 has risen by 65.0% from the previous average of $4.00. The analysts have an average rating of 'neutral' for the company and a 'buy' on the stock. The firm has an average revenue growth rate of -27.14%.
Benzinga · 03/19 13:00
Mersana Therapeutics Raised to Neutral From Underweight by JP Morgan
Dow Jones · 03/19 10:00
Mersana Therapeutics Price Target Announced at $5.00/Share by JP Morgan
Dow Jones · 03/19 10:00
JP Morgan Upgrades Mersana Therapeutics to Neutral, Announces $5 Price Target
Benzinga · 03/19 09:50
U.S. RESEARCH ROUNDUP-American Tower, Lennar, Nike
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. American Tower, Lennar and Nike among companies with revised targets on Tuesday. Analysts cut target prices for American Tower and Lennar, raise targets for others. Zoom Video Communications, Darden Restaurants and others also see analyst downgrades.
Reuters · 03/19 07:17
Weekly Report: what happened at MRSN last week (0311-0315)?
Weekly Report · 03/18 09:04
12 Health Care Stocks Moving In Friday's After-Market Session
Cue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. Aclarion and SCWorx stock rose by 10.39% and 7.55% respectively.
Benzinga · 03/15 21:33
AVLX, SGH and ETNB are among pre market losers
On the Move AVLX, SGH and ETNB are among pre market losers. 89bio and iHeartMedia are among the pre market gainers. CERo Therapeutics Holdings and Castle Biosciences are among those that lost in the biotech sector.
Seeking Alpha · 03/15 20:48
Mersana Therapeutics (MRSN) Gets a Buy from Truist Financial
TipRanks · 03/12 12:37
Weekly Report: what happened at MRSN last week (0304-0308)?
Weekly Report · 03/11 09:04
Top 10 best performing biotech stocks of 2024 so far
The biotech sector is +13.6% in 2024. Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors and computer peripherals industries. Top 10 best performing biotech stocks of 2024 so far are Elevation Oncology and Janux.
Seeking Alpha · 03/06 16:25
Weekly Report: what happened at MRSN last week (0226-0301)?
Weekly Report · 03/04 09:04
Buy Rating Affirmed for Mersana Therapeutics Amid Promising ADC Developments and Upcoming Milestones
TipRanks · 03/01 06:07
Truist Securities Upgrades Mersana Therapeutics (MRSN)
NASDAQ · 03/01 03:18
Guggenheim Upgrades Mersana Therapeutics (MRSN)
NASDAQ · 03/01 03:18
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Butterfly Network, Inc. Shares dipped 21.7% to $1.1588 on Thursday. The company reported mixed fourth-quarter financial results. Enveric Biosciences gained 177.1% in Thursday's mid-day session. Volcon shares rose 55.4% after surging around 39% on Wednesday.
Benzinga · 02/29 19:00
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
Shares of Hormel Foods Corporation (HRL) rose sharply after the company reported better-than-expected first-quarter earnings. The Nasdaq Composite gained around 50 points on Thursday. Vertex, Inc. Shares jumped 29.8% to $32.97 after reporting strong quarterly results.
Benzinga · 02/29 16:30
Mersana Therapeutics Price Target Raised to $7.00/Share From $2.00 by Wedbush
Dow Jones · 02/29 16:01
Mersana Therapeutics Raised to Outperform From Neutral by Wedbush
Dow Jones · 02/29 16:01
More
Webull provides a variety of real-time MRSN stock news. You can receive the latest news about Mersana Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.